Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: retrospective analysis of an initial experience

Mayo Clinic Proceedings

Volumn 71, Issue 12, 1996, Pages 1150-1154

  Arsenault, Todd M ^a   King, Bernard F ^a,c   Wallis Marsh, J ^a,b   Goodman, Judith A ^c,e   Weaver, Amy L ^c   Wood, Christopher P ^d   Ehman, Richard L ^a  

^a Department of Diagnostic Radiology ^*  (United States)

^b Quality Information Resource Center   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DTPA DIMEGLUMINE; GADOLINIUM; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE MARKER; DRUG ELIMINATION; DRUG SAFETY; HEADACHE; HUMAN; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MORTALITY; NAUSEA; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; RASH; SEIZURE;

EID: 0030317246     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/71.12.1150     Document Type: Article

References (17)

1. Niendorf HP, Haustein J, Cornelius I, Alhassan A, Clauss W. Safety of gadolinium-DTPA: extended clinical experience. Magn Reson Med 1991; 22:222-228
2. Goldstein HA, Kashanian FK, Blumetti RF, Holyoak WL, Hugo FP, Blumenfield DM. Safety assessment of gadopentetate dimeglumine in U.S. clinical trials. Radiology 1990; 174:17-23
3. Weinmann HJ, Laniado M, Mutzel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984; 16:167-172
4. Schuhmann-Giampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 1991; 26:975-979
5. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990; 8:467-481
6. Unger EC, Fritz TA, Tilcock C, New TE. Clearance of liposomal gadolinium: in vivo decomplexation. J Magn Reson Imaging 1991; 1:689-693
7. Siegel S. Nonparametric Statistics for the Behavioral Sciences. New York: McGraw-Hill, 1956:75-83
8. Tweedle MF, Hagan JJ, Kumar K, Mantha S, Chang CA. Reaction of gadolinium chelates with endogenously available ions. Magn Reson Imaging 1991; 9:409-415
9. Rocklage SM, Worah D, Kim SH. Metal ion release from paramagnetic chelates: what is tolerable? Magn Reson Med 1991; 22:216-221
10. Wedeking P, Kumar K, Tweedle MF. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magn Reson Imaging 1992; 10:641-648
11. Weiss KL, Jhaveri HS. Severe anaphylactoid reaction after IV Gd DTPA [abstract]. Magn Reson Imaging 1990; 8(Suppl 1):81
12. Tardy B, Guy C, Barrai G, Page Y, Ollagnier M, Bertrand JC. Anaphylactic shock induced by intravenous gadopentetate dimeglumine [letter). Lancet 1992; 339:494
13. Tishler S, Huffman JC Jr. Anaphylactoid reactions to IV gadopentetate dimeglumine. AJNR Am J Neuroradiol 1990; 11:1167
14. Takebayashi S, Sugiyama M, Nagase M, Matsubara S. Severe adverse reaction to iv gadopentetate dimeglumine [letter]. AJR Am J Roentgenol 1993; 160:659
15. Segall HD, Ball WS Jr, Destian S, Elster AD, Gebarski SS, Jinkins JR, et al. MR contrast agents: who needs them at all, and who needs the new ones? [RSNA '92 meeting notes]. Radiology 1993; 186:940-948
16. Haustein J, Niendorf HP, Krestin G, Louton T, SchuhmannGiampieri G, Clauss W, et al. Renal tolerance of gadoliniumDTPA/dimeglumine in patients with chronic renal failure. Invest Radiol 1992; 27:153-156
17. Rofsky NM, Weinreb JC, Bosniak MA, Libes RB, Birnbaum BA. Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency. Radiology 1991; 180:85-89